Celgene Corp. (NASDAQ:CELG) traded up 4.1% on Wednesday . The stock traded as high as $104.94 and last traded at $104.32, with a volume of 4,226,863 shares traded. The stock had previously closed at $100.25.

Several equities research analysts have weighed in on the company. Robert W. Baird reiterated a “buy” rating and issued a $162.00 price objective on shares of Celgene Corp. in a report on Tuesday, April 26th. Bank of America Corp. reiterated a “buy” rating and issued a $125.00 price objective on shares of Celgene Corp. in a report on Monday, April 25th. Vetr cut Celgene Corp. from a “strong-buy” rating to a “buy” rating and set a $120.74 price objective for the company. in a report on Thursday, June 2nd. SunTrust Banks Inc. reiterated a “buy” rating and issued a $147.00 price objective (up previously from $145.00) on shares of Celgene Corp. in a report on Thursday, April 28th. Finally, Raymond James Financial Inc. restated a “buy” rating on shares of Celgene Corp. in a research note on Thursday, April 28th. Six equities research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company’s stock. Celgene Corp. currently has a consensus rating of “Buy” and a consensus target price of $140.62.

The stock has a market cap of $80.51 billion and a P/E ratio of 50.552. The company has a 50 day moving average price of $102.21 and a 200-day moving average price of $104.07.

Celgene Corp. (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.03. The company had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.59 billion. Celgene Corp.’s revenue for the quarter was up 20.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.07 earnings per share. Analysts anticipate that Celgene Corp. will post $5.68 EPS for the current fiscal year.

In other news, insider Robert J. Hugin sold 75,000 shares of the firm’s stock in a transaction dated Monday, June 20th. The stock was sold at an average price of $100.16, for a total transaction of $7,512,000.00. Following the sale, the insider now directly owns 1,122,201 shares in the company, valued at approximately $112,399,652.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Other hedge funds and institutional investors recently modified their holdings of the company. Synovus Financial Corp raised its position in shares of Celgene Corp. by 16.6% in the fourth quarter. Synovus Financial Corp now owns 8,571 shares of the biopharmaceutical company’s stock worth $1,027,000 after buying an additional 1,222 shares in the last quarter. Lee Danner & Bass Inc. raised its position in Celgene Corp. by 226.4% in the fourth quarter. Lee Danner & Bass Inc. now owns 8,650 shares of the biopharmaceutical company’s stock worth $1,036,000 after buying an additional 6,000 shares during the period. WMS Partners LLC raised its position in Celgene Corp. by 20.9% in the fourth quarter. WMS Partners LLC now owns 8,669 shares of the biopharmaceutical company’s stock worth $1,038,000 after buying an additional 1,500 shares during the period. Investment Management of Virginia LLC raised its position in Celgene Corp. by 63.0% in the fourth quarter. Investment Management of Virginia LLC now owns 9,043 shares of the biopharmaceutical company’s stock worth $1,083,000 after buying an additional 3,495 shares during the period. Finally, NBT Bank N A NY raised its position in Celgene Corp. by 0.3% in the fourth quarter. NBT Bank N A NY now owns 9,248 shares of the biopharmaceutical company’s stock worth $1,107,000 after buying an additional 30 shares during the period.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.